International Journal of Clinical Oncology

, Volume 16, Issue 5, pp 605–609 | Cite as

Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases

  • Masashi TakanoEmail author
  • Yoshihiro Kikuchi
  • Kazuya Kudoh
  • Tomoko Goto
  • Kenichi Furuya
  • Ryoko Kikuchi
  • Tsunekazu Kita
  • Keiichi Fujiwara
  • Tanri Shiozawa
  • Daisuke Aoki
Case Report


Clear cell carcinoma (CCC) of the ovary is well-known to be chemotherapy resistant compared with other histologic subtypes. An inhibitor against the mammalian target of rapamycin, temsirolimus (TEM) has been reported to be effective in renal CCC. Therefore, we investigated the effects of TEM in patients with CCC of the ovary. Six patients with CCC of the ovary who had been heavily pretreated by more than 4 regimens were given TEM: the cycle consisted of weekly TEM (10 mg/m2) for 3 weeks followed by 1 week off. The treatment was continued until development of either progressive disease, or unmanageable adverse effects. Response evaluation was based upon the Response Evaluation Criteria in Solid Tumors version 1.0. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events version 3.0. The median cycle of weekly TEM was 3 (range 2–14). Among five cases in which responses could be evaluated, partial response was observed in one case (20%) and stabilized disease was seen in another case (20%). There were no toxicities greater than grade 3, and no case developed severe toxicity requiring discontinuation of weekly TEM. The patient who showed a partial response obtained a progression-free period of 14 months. In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial.


Temsirolimus mTOR inhibitor Ovarian clear cell carcinoma Recurrence Refractory 


Conflict of interest

No author has any conflict of interest.


  1. 1.
    Goff BA, Sainz de la Cuesta R, Muntz HG et al (1996) Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60:412–417PubMedCrossRefGoogle Scholar
  2. 2.
    Recio FO, Piver MS, Hempling RE et al (1996) Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum-based chemotherapy. Cancer 78:2157–2163PubMedCrossRefGoogle Scholar
  3. 3.
    Sugiyama T, Kamura T, Kigawa J et al (2000) Clinical characteristics of clear cell carcinoma of the ovary. Cancer 88:2584–2589PubMedCrossRefGoogle Scholar
  4. 4.
    Pectasides D, Fountzilas G, Aravantinos G et al (2006) Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol 102:285–291PubMedCrossRefGoogle Scholar
  5. 5.
    Enomoto T, Kuragaki C, Yamasaki M et al (2003) Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22:abstr 1797Google Scholar
  6. 6.
    Ho CM, Huang YJ, Chen TC et al (2004) Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol 94:197–203PubMedCrossRefGoogle Scholar
  7. 7.
    Takano M, Sugiyama T, Yaegashi N et al (2008) Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer 18:937–942PubMedCrossRefGoogle Scholar
  8. 8.
    Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRefGoogle Scholar
  9. 9.
    Bellmunt J, Szczylik C, Feingold J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387–1392PubMedCrossRefGoogle Scholar
  10. 10.
    Malizzia LJ, Hsu A (2008) Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clin J Oncol Nurs 12:639–646PubMedCrossRefGoogle Scholar
  11. 11.
    Lee S, Garner EI, Welch WR et al (2007) Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 106:311–317PubMedCrossRefGoogle Scholar
  12. 12.
    Miyazawa M, Yasuda M, Fujita M et al (2009) Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 59:19–27PubMedCrossRefGoogle Scholar
  13. 13.
    Mabuchi S, Kawase C, Altomare DA et al (2009) mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 15:5404–5413PubMedCrossRefGoogle Scholar
  14. 14.
    Rustin GJ (2003) Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21(10 Suppl):187s–193sPubMedCrossRefGoogle Scholar
  15. 15.
    Takano M, Kikuchi Y, Yaegashi N et al (2006) Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer 94:1369–1374PubMedCrossRefGoogle Scholar
  16. 16.
    Kuo KT, Guan B, Feng Y et al (2009) Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res 69:4036–4042PubMedCrossRefGoogle Scholar
  17. 17.
    Osada R, Horiuchi A, Kikuchi N et al (2007) Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 38:1310–1320PubMedCrossRefGoogle Scholar
  18. 18.
    Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103:253–262PubMedCrossRefGoogle Scholar
  19. 19.
    Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004–7014PubMedCrossRefGoogle Scholar
  20. 20.
    Harding MW (2003) Immunophilins, mTOR, and pharmacodynamic strategies for a targeted cancer therapy. Clin Cancer Res 9:2882–2886PubMedGoogle Scholar
  21. 21.
    Del Bufalo D, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549–5554PubMedCrossRefGoogle Scholar
  22. 22.
    Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336–2347PubMedCrossRefGoogle Scholar
  23. 23.
    Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918PubMedCrossRefGoogle Scholar
  24. 24.
    Crotzer DR, Sun CC, Coleman RL et al (2007) Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol 105:404–408PubMedCrossRefGoogle Scholar
  25. 25.
    Utsunomiya H, Akahira J, Tanno S et al (2006) Paclitaxel–platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial. Int J Gynecol Cancer 16:52–56PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2011

Authors and Affiliations

  • Masashi Takano
    • 1
    Email author
  • Yoshihiro Kikuchi
    • 2
  • Kazuya Kudoh
    • 3
  • Tomoko Goto
    • 1
  • Kenichi Furuya
    • 1
  • Ryoko Kikuchi
    • 4
  • Tsunekazu Kita
    • 5
  • Keiichi Fujiwara
    • 6
  • Tanri Shiozawa
    • 7
  • Daisuke Aoki
    • 8
  1. 1.Department of Obstetrics and GynecologyNational Defense Medical CollegeTokorozawaJapan
  2. 2.Department of GynecologyOhki Memorial Kikuchi Cancer Clinic for WomenTokorozawaJapan
  3. 3.Department of Obstetrics and GynecologyNishisaitama-chuo National HospitalTokorozawaJapan
  4. 4.Department of Basic PathologyNational Defense Medical CollegeTokorozawaJapan
  5. 5.Department of Obstetrics and GynecologyNara Prefectural Nara HospitalNaraJapan
  6. 6.Department of Gynecologic OncologySaitama Medical University International Medical CenterSaitamaJapan
  7. 7.Department of Obstetrics and GynecologyShinshu University School of MedicineMatsumotoJapan
  8. 8.Department of Obstetrics and GynecologyKeio University School of MedicineTokyoJapan

Personalised recommendations